<DOC>
	<DOCNO>NCT00425204</DOCNO>
	<brief_summary>A multi-center , open-label , extended treatment , clinical trial examine safety administer multiple panitumumab intravenous ( i.v . ) infusion patient previously receive panitumumab benefit treatment</brief_summary>
	<brief_title>Study Patients Who Have Benefited Tolerated Prior Panitumumab Treatment</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>Able comprehend sign IRB approve Informed Consent Form Male female 18 year age old Female patient post menopausal ( menstrual period minimum six month ) , surgically sterilize , use oral implanted contraceptive , double barrier birth control , intrauterine device ( IUD ) negative serum pregnancy test upon entry study ; male patient willing use contraception upon enrollment course study Previously receive tolerated panitumumab treatment study 20020374 Part 2 20030138/20040116 Is consider `` stable '' `` respond '' base RECIST ( 20020374 Part 2 ) WHO ( 20040116 ) criterion , final treatment visit previous panitumumab clinical trial screen visit study No 2 month ( 60 day ) elapse since final treatment visit previous panitumumab clinical trial Karnofsky score &gt; = 70 % Brain metastasis ( 20040116 patient allow controlled asymptomatic ) Uncontrolled hypercalcemia ( calcium level outside upper limit normal ; antihypercalcemic treatment allow ) . Exception : Patients Motzer Intermediate Risk Group 20020374 Cohort 2 uncontrolled high correct calcium ( &gt; 10 mg/dl ) may enrol Use antitumor therapy investigational drug , panitumumab , last visit previous panitumumab study initial visit 20020375 study Prior treatment another antiEGFr agent , panitumumab Myocardial infarction within 1 year prior enter study Has cancer active require treatment within past 5 year ( basal cell carcinoma cervical carcinoma situ allow ) Pregnant breast feed female ; female childbearing potential ( define : post menarche biologically capable become pregnant ) unwilling use birth control ( define inclusion criterion ) 6 month follow treatment Male patient unwilling use birth control ( define inclusion criterion ) 1 month follow treatment Known HIV positive History chronic medical psychiatric condition laboratory abnormality opinion Investigator may increase risk associated study drug administration Allergy ingredient study medication Staphylococcus Protein A History interstitial pneumonitis pulmonary fibrosis evidence interstitial pneumonitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
</DOC>